Papers
Trial and study results from the journals, in the order we post them.
October 2026
- Can we safely combine radiotherapy with antibody-drug conjugates—or does the specific ADC change the risk?Breast
Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis
Breast. Study result. Radiotherapy & Oncology. October 15, 2026.
- Are we underestimating aggressive prostate cancer by missing its most important histological warning signs?Genitourinary
Cribiform and intraductal carcinoma in prostate cancer-implications for risk stratification and therapeutic decision making (REVIEW)
Genitourinary. Study result. Nature Reviews Urology. October 15, 2026.
- Is precision breast cancer care entering a new era, or are complexity, biomarker uncertainty, and unequal access holding it back?Breast
Advances in Systemic Treatment of Breast Cancer (Review)
Breast. Study result. NEJM. October 12, 2026.
- Can combining targeted radioligand therapy with SBRT more than double progression-free survival in oligorecurrent prostate cancer?Genitourinary
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR)
Genitourinary. Study result. Journal of Clinical Oncology. October 12, 2026.
- Can a blood test detect cancer earlier—but still fail to demonstrate clinical utility?Breast
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Breast. Study result. NEJM. October 9, 2026.
- Could immune biology finally tell us which patients with extensive-stage SCLC are most likely to benefit from TIGIT-based therapy?Lung and thoracic
SKYSCRAPER-02C A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China
Lung and thoracic. Study result. Journal if Thoracic Oncology. October 7, 2026.
- immunotherapy while others rapidly develop resistance?Breast
A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics
Breast. Study result. CellPress. October 7, 2026.
- What if metastatic bladder cancer spreads not just from the primary tumour, but continuously from one metastasis to another?Genitourinary
Evolution and heterogeneity of lethal metastatic bladder cancer subtypes
Genitourinary. Study result. Nature. October 6, 2026.
- Is perioperative immunotherapy finally changing the standard of care in resectable gastric cancer?Head and neck
Final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Head and neck. Trial result. The Lancet. October 6, 2026.
- Does adding immunotherapy to SBRT actually improve outcomes in early-stage, medically inoperable NSCLC or simply add toxicity?Lung and thoracic
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
Lung and thoracic. Trial result. The Lancet. October 5, 2026.
- Could targeting both ER and PI3K–AKT–mTOR pathways help overcome endocrine resistance?Breast
Giredestrant plus Everolimus in Advanced Breast Cancer
Breast. Trial result. NEJM. October 3, 2026.
- Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced RCCGenitourinary
Could biomarkers help us better identify which patients with advanced RCC are most likely to benefit from immunotherapy?
Genitourinary. Study result. October 3, 2026.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.